-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Unleashing Emerging Therapies to Modify Myelofibrosis Pathogenesis: Shifting the Treatment Paradigm to Target Deeper Clinical and Molecular Responses

Sponsor: PRIME Education, LLC
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Therapy sequence, Treatment Considerations, Biological therapies
Friday, December 6, 2024: 3:00 PM-6:00 PM
Room 6DE (San Diego Convention Center)
Chair:
Jeanne Palmer, MD, Mayo Clinic - Arizona
Disclosures:
No relevant conflicts of interest to declare.
Speakers:
Douglas Burgoyne, PharmD, FAMCP, University of Utah , Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai , Jeanne Palmer, MD, Mayo Clinic - Arizona and Pankit Vachhani, MD, University of Alabama at Birmingham
Disclosures:
No relevant conflicts of interest to declare.

Join expert faculty as they take a deep dive into the latest clinical evidence and practical considerations for the personalized treatment of patients with myelofibrosis (MF) with JAK inhibitors and beyond. Informed by the diverse molecular targets and rationale for emerging MF therapies in late-stage clinical investigation, this satellite symposium will feature a review of the novel mechanisms of action and disease modifying potential of emerging MF therapies that will be reinforced through interactive polling questions and a 2D animation video, as well as expert insights on the potential positioning of these agents into MF treatment plans. Additionally, participants will have access to an up-to-date Myelofibrosis Clinical Trial Pocket Guide alongside the symposium to support the differentiation of the evolving landscape based on mechanisms of action, clinical trial design, and disease-modifying endpoints. Altogether, this satellite symposium is designed to prepare providers for the MF treatment paradigm shift, bringing combination therapy and disease modification to the forefront of patient-centered cares and durable outcomes.